8-K: PROCEPT BioRobotics Reports Strong Q3 2025 Results

PROCEPT BioRobotics Corporation announced robust third-quarter 2025 financial results, with total revenue increasing 43% year-over-year and issued optimistic 2026 revenue guidance.

Summary

• Total revenue for the third quarter of 2025 was $83.3 million, an increase of 43% compared to the prior year period.
• U.S. handpiece and consumables revenue reached $44.4 million for Q3 2025, up 50% year-over-year.
• The U.S. install base increased by 58 robotic systems in Q3 2025, bringing the total to 653 systems as of September 30, 2025.
• International revenue grew by 53% to $9.4 million for the third quarter.
• Gross margin for Q3 2025 was 65%, an improvement from 63% in the prior year period.
• Operating expenses in Q3 2025 were $77.2 million, compared to $59.3 million in the prior year, driven by commercial expansion, R&D, G&A, and executive leadership transition costs.
• Net loss for Q3 2025 was $21.4 million, a slight increase from a loss of $21.0 million in the prior year period.
• Adjusted EBITDA was a loss of $7.4 million for Q3 2025, an improvement from a loss of $12.4 million in the prior year period.
• Cash, cash equivalents, and restricted cash totaled $297.3 million as of September 30, 2025.
• The company reiterated its fiscal year 2025 total revenue guidance of approximately $325.5 million, representing 45% growth over 2024.
• Fiscal year 2026 total revenue guidance was issued in the range of $410 to $430 million, projecting 26% to 32% growth compared to fiscal 2025 guidance.

Sentiment

Score: 8

Explanation: The company reported strong revenue growth, improved gross margins, and a significantly narrowed Adjusted EBITDA loss. The positive 2026 revenue guidance further reinforces a strong outlook, despite a slight increase in net loss and higher operating expenses due to strategic growth investments.

Positives

• Strong total revenue growth of 43% year-over-year to $83.3 million in Q3 2025.
• Significant increase in U.S. handpiece and consumables revenue by 50% to $44.4 million, indicating strong utilization.
• Robust expansion of the U.S. install base with 58 new robotic systems in Q3 2025, reaching 653 systems.
• High international revenue growth of 53% to $9.4 million.
• Improved gross margin to 65% in Q3 2025 from 63% in the prior year, driven by operational efficiencies.
• Reduced Adjusted EBITDA loss to $7.4 million in Q3 2025 from $12.4 million in the prior year, showing improved operational leverage.
• Positive 2026 revenue guidance projecting 26% to 32% growth, indicating continued strong outlook.

Negatives

• Net loss slightly increased to $21.4 million in Q3 2025 from $21.0 million in the prior year period.
• Operating expenses increased to $77.2 million from $59.3 million, primarily due to investments in commercial organization expansion, R&D, G&A, and one-time executive leadership transition expenses.
• Anticipated gross margin headwind of approximately $2.0 million in Q4 2025 due to tariff-related costs.

Risks

• Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from anticipated results and expectations.
• Risks and uncertainties are described more fully in the 'Risk Factors' section of the company's filings with the SEC, including the annual report on Form 10-K and subsequent quarterly reports on Form 10-Q.

Future Outlook

The company reiterates its full-year 2025 total revenue guidance of approximately $325.5 million, representing 45% growth over the prior year. For fiscal year 2026, total revenue is projected to be in the range of $410 to $430 million, indicating growth of 26% to 32% compared to the 2025 guidance. Full year 2025 gross margins are expected to be 64.0% to 64.5%, with an anticipated $2.0 million headwind in Q4 due to tariff-related costs. Full year 2025 total operating expense is expected to be approximately $302.0 million, and Adjusted EBITDA loss is projected to be approximately ($35.0) million. Management remains focused on expanding awareness of Aquablation therapy, driving patient activation, and advancing its mission.

Management Comments

• "In my initial weeks as CEO, I am pleased to report we delivered a strong performance. We accelerated U.S. system placements, demonstrating strong demand for the HYDROS Robotic System, and achieved 43% year over year global revenue growth." Larry Wood, Chief Executive Officer.
• "This quarter's results underscore the strength of our business and the growing adoption of Aquablation therapy. My first two months at PROCEPT have only deepened my confidence in our significant growth potential. We remain focused on expanding awareness of Aquablation therapy, driving patient activation and advancing our mission." Larry Wood, Chief Executive Officer.

Industry Context

PROCEPT BioRobotics operates in the specialized surgical robotics market, focusing on urology and the treatment of Benign Prostatic Hyperplasia (BPH). The strong revenue growth and increasing adoption of Aquablation therapy, particularly the HYDROS Robotic System, indicate a positive trend for innovative, minimally invasive solutions in the medical device sector. The company's strategy to expand awareness and drive patient activation aims to capture a larger share of the BPH market, which affects a significant male population. The AI-Powered Aquablation therapy positions the company as a leader in technological advancement within this niche, suggesting a competitive edge in a growing market for advanced medical procedures.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Likely positive impact due to strong revenue growth, improved gross margins, narrowed Adjusted EBITDA loss, and optimistic future guidance, potentially leading to increased share value.
• Customers (Hospitals/Urologists): Continued strong demand and increased install base suggest high satisfaction and growing adoption of the HYDROS Robotic System and Aquablation therapy.
• Patients: Growing adoption of Aquablation therapy indicates more patients are benefiting from the effective and safe treatment for BPH.
• Employees: Expansion of the commercial organization implies potential for job growth and stability within the company.

Next Steps

• Host a conference call to discuss the third quarter 2025 financial results on Tuesday, November 4, 2025, at 4:30 p.m. Eastern Time.
• Continue expanding awareness of Aquablation therapy.
• Drive patient activation for Aquablation therapy.
• Advance the company's mission in urology.

Key Dates

Recommendation

The company demonstrated exceptional revenue growth of 43% year-over-year, driven by strong U.S. system placements and increased handpiece utilization. Gross margins expanded, and the Adjusted EBITDA loss significantly narrowed, indicating improving operational efficiency and a clear path towards profitability. The robust 2026 revenue guidance, projecting 26-32% growth, reinforces confidence in sustained momentum. While net loss slightly increased due to growth investments, the underlying business performance and market adoption of Aquablation therapy are very strong, making it an attractive investment for long-term growth.

Keywords

PROCEPT BioRobotics, PRCT, surgical robotics, urology, Aquablation therapy, HYDROS Robotic System, BPH treatment, financial results, revenue guidance, Q3 2025 earnings